雌激素在肺淋巴管平滑肌瘤病发病机制中的研究进展  

Role of estrogen in pulmonary lymphangioleiomyomatosis

作　　者：王坚[1] 叶伶[1] 牟艳[1] 金美玲[1] 

机构地区：[1]复旦大学附属中山医院呼吸科,上海200032

出　　处：《国际呼吸杂志》2014年第22期1737-1741,共5页International Journal of Respiration

基　　金：上海市重点学科建设项目资助（B115）

摘　　要：肺淋巴管平滑肌瘤病是一种罕见的弥漫性的肺部疾病，病因未明，目前尚无有效的治疗方法。现已发现肺淋巴管平滑肌瘤病几乎只发生于育龄期的女性，与体内雌激素水平密切相关，但是目前雌激素对肺淋巴管平滑肌瘤病的作用机制尚未完全清楚。本文就新近的研究结果阐述雌激素的作用机制，为肺淋巴管平滑肌瘤病的治疗提供新的方向。Pulmonary lymphangioleiomyomatosis （PLAM） is a rare disease which presents the diffuse progressive destruction to the pulmonary parenchyma. None effective treatments are currently proposed for this disease. PLAM occurs almost exclusively in women in the childbearing years, so it indicates that the disease is closely associated with estrogen. As the mechanism of the function of estrogen in PLAM has not been clarified entirely,the latest studies will be reviewed to increase the awareness to the effect of estrogen on PLAM and to advance the development of new therapeutic strategies.

关 键 词：雌激素 肺淋巴管平滑肌瘤病 发病机制 

分 类 号：R734.2[医药卫生—肿瘤]